Related Articles
Clinical Trial Experiences of Patients
POMPE PROGRAM UPDATE MAY 22, 2009
Pompe Program Update March 2, 2009
Genzyme Receives Complete Response Letter from FDA on Lumizyme Application
MYOZYME® (2000 L) SUPPLY UPDATE _US VERSION_JANUARY 2009
GUIDANCE TO THE POMPE COMMUNITY ON THE MANAGEMENT OF MYOZYME SUPPLY
GENZYME POMPE PROGRAM UPDATE NOVEMBER 17, 2008
MYOZYME PRODUCED AT THE 2000L BIOREACTOR SCALE TO RECEIVE ACCELERATED APPROVAL
Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
Genzyme Provides Update on Myozyme® Manufacturing
Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
REHABILITATION MANAGEMENT OF POMPE DISEASE: GREGORY T. CARTER, MD, MS
JOINT LETTER FROM THE AMDA AND UPF
MYOZYME® TEMPORARY ACCESS PROGRAM (MTAP) UPDATES
MYOZYME® TEMPORARY ACCESS PROGRAM
THE MYOZYME MIRACLE
FDA APPROVES GENZYMES MYOZYME® FOR ALL PATIENTS WITH POMPE DISEASE
Expensive drug gives hope to rare disease sufferer
HOME ADAPTIONS: SHARON KRUEGER
Canadian Association of Pompe
"WEAKLING WILLIE" BOOK
FLYING WITH A VENTILATOR IN THE USA
Association for Glycogen Storage Disease
JUAN MAGDARAOG BLOG
Myozyme Home Page
EXPRESSION OF HOPE
Amicus Therapeutics
UK Pompe Group
Helping Hands Loving Hearts
International Pompe Association IPA
Clinical Trial Information
Genzyme's Pompe Website
